Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study
Introduction : Omalizumab, a monoclonal anti-immunoglobulin E antibody, has been successfully used as a supplementary therapy to improve asthma control in children aged ≥ 6 years with severe persistent allergic asthma. Aim : To demonstrate the quality of life in children with severe asthma and the...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2017-10-01
|
| Series: | Advances in Dermatology and Allergology |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Quality-of-life-in-asthmatic-children-and-their-caregivers-after-two-year-treatment-with-omalizumab-a-real-life-study,7,30902,1,1.html |